Waldenstrom Macroglobulinemia (WM) cells present with increased expression of miRNA-206 and reduced expression of miRNA-9*. Predicted miRNA-206 and -9*-targeted-genes include HDACs and HATs, indicating that these microRNA (miRNA) may play a role in regulating histone acetylation. We were able to demonstrate that primary WM cells are characterized by unbalanced expression of histone deacetylases (HDACs) and histone acetyl transferases (HATs), responsible for decreased acetylatedhistone-H3 and -H4, and increased HDAC-activity. We next examined whether miRNA-206 and -9* modulate the aberrant expression of HDAC and HATs in WM cells leading to increased transcriptional activity. We found that restoring miRNA-9* levels, by transfecting WM cells with precursor-miRNA-9*, induced toxicity in WM cells, supported by down-modulation of HDAC4 and HDAC5 and up-regulation of acetylhistone-H3 and -H4. These, together with inhibited HDAC-activity, led to induction of apoptosis and autophagy in WM cells. To further confirm that miRNA-9*-dependent modulation of histone acetylation is responsible for induction of WM cytotoxicity, a novel class of HDAC inhibitor (LBH589) was used; we confirmed that inhibition of HDAC-activity leads to toxicity in this disease. These findings confirm that histonemodifying genes and HDAC-activity are de-regulated in WM cells, partially driven by the aberrant expression of miRNA-206 and -9* in the tumor clone.
INTRODUCTION
Waldenstrom Macroglobulinemia (WM) is a B cell low-grade lymphoma characterized by an arrest of B cells after somatic hypermutation and before isotype class switching. 1, 2 Characterization of the cytogenetic and genetic abnormalities in WM has led to the identification of the long arm deletion on chromosome 6 (6q-) in about 35% of the patients with this disease through the use of fluorescent in situ hybridization (FISH). 3 However, other cytogenetic and chromosomal abnormalities that are common in plasma cell dyscrasias, including multiple myeloma or in other low-grade B cell malignancies, are not present in WM. Gene expression profiling in these patients has also been able to show that there are minimal genetic changes, with an expression profile similar to chronic lymphocytic leukemia myeloma. 4 Therefore, multi-level characterization of this disease at the epigenetic level is necessary to better identify molecular abnormalities that lead to tumor progression and survival in this disease.
Epigenetic alterations include methylation, histone acetylation, and microRNA (miRNA) regulation. 5 Histone acetylation is commonly deregulated in many cancers. The balance of nucleosomal histone acetylation leads to the transcriptional regulation of many genes:
hypoacetylation is associated with a condensed chromatin structure leading to the repression of gene transcription, and acetylation is associated with a more open chromatin structure and activation of transcription. 6, 7 This balance is maintained by a tight regulation of the level of histone deacetylase (HDAC) and histone acetyl transferases (HATs). In many malignancies, this balance is deregulated, with an increased expression of HDACs leading to enhanced gene transcription. 8, 9 HDACs are enzymes that catalyze the removal of the acetyl modification on lysine residues of proteins, including the nucleosomal histones H2A, H2B, H3, and H4. In addition, other induced genes include the cell cycle kinase inhibitor p21 WAF1 , p16 ink4a , and p27
Kip , p53, NF-YA, and GATA-1, leading to enhanced cellular functions such as proliferation, cell-cycle, and survival. 10 Recent report has demonstrated that WM cells present with a specific miRNA signature characterized by increased expression of miRNA-206 and reduced expression of miRNA-9*. 11 Predicted miRNA-206 and -9*-targeted-genes include HDACs and
HATs, leading us to hypothesize that miRNA-206 and -9* play a role in regulating
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In this study, we investigate the role of miRNA-206 and -9* in the regulation of histone modification in WM. We first demonstrated that primary WM cells are characterized by unbalanced expression of HDACs and HATs at the mRNA level. We found that restoring miRNA-9* levels, by transfecting WM cells with precursor-miRNA-9*, resulted in induction of toxicity in WM cells, supported by down-modulation of HDAC4 and HDAC5 and up-regulation of acetyl-histone-H3 and -H4. These, together with inhibited HDAC activity, led to induction of apoptosis and autophagy in WM cells.
MATERIALS AND METHODS

Cells
WM cell line (BCWM.1) and IgM secreting low grade lymphoma cell lines (WM-WSU, MEC-1 and RL) were used in this study. The BCWM.1 is a recently described WM cell line that has been developed from a patient with untreated WM. 12 MEC-1 was a gift from Dr. Kay (Mayo Clinic, Rochester, MN). RL was purchased from the American Tissue Culture Collection (Manassas, VA). Primary WM cells were obtained from bone marrow (BM) samples using CD19+ microbead selection (Miltenyi Biotec, Auburn, CA) with over 90% purity, as confirmed by flow cytometric analysis with monoclonal antibody reactive to human CD20-PE (BD-Bioscience, San Jose, CA), as described. 13 Peripheral blood mononuclear cells (PBMCs) were obtained from healthy subjects by FicollHipaque density sedimentation, and subsequently CD19+ selection was performed as described above. All cell lines and primary cells were cultured at 37ºC in RPMI-1640 containing 10% fetal bovine serum (FBS; Sigma Chemical, St Louis, MO), 2 mM Lglutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (GIBCO, Grand Island, NY 
HDAC activity assay
HDAC activity was determined by using Colorimetric HDAC Activity Assay Kit.
(BioVision, Mountain View, CA), as described.
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Gene expression profiling
Total RNA has been isolated from primary CD19+ cells isolated from bone marrow of patients with Waldenstrom Macroglobulinemia and from peripheral blood mononuclear cells of healthy donors, using RNeasy kit (Qiagen), as described by the manufacturer.
Purified cRNA (15 μg) was hybridized to HG-U133Plus2.0 GeneChip (Affimetrix). RNA integrity was verified with the Agilent 2100 Bioanalyzer (Agilent, CA, USA).
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microRNA expression profiling RNA was isolated using an RNeasy kit (Qiagen, Valencia, CA), as reported in previous miRNA studies. [16] [17] [18] The expression of 318 miRNAs was investigated using liquid phase Luminex microbead miRNA profiling (Luminex, Austin, TX), as described. 19 Briefly, 500 ng of total RNA was labeled with biotin using the FlexmiR MicroRNA labeling kit (Luminex, Austin, TX), which labeled all RNA molecules including small RNA, by first using Calf Intestinal Phosphatase (CIP) for removal of 5'-phosphatases from the terminal end of the miRNAs. In the second step, a biotin label was then attached enzymatically to the 3'-end of the miRNAs in the total RNA sample. After an enzyme inactivation step, Efficiency of transfection was validated by qRT-PCR and microRNA assay.
Growth inhibition assay
The inhibitory effect of LBH589 on WM cell growth was assessed by measuring 3-(4,5- 
Effect on paracrine WM cells growth in the BM
To evaluate the role of miRNA-9* and HDAC inhibition in regulating growth in WM cells in the context of primary bone marrow stromal cells (BMSCs), untransfected, scramble probe-and pre-miRNA-9*-transfected BCWM.1 cells were cultured in presence or absence of BMSCs for 48 hours. DNA synthesis was measured as previously described. 13 Similarly, BCWM.1 cells were cultured in BMSC-coated 96-well plates for 48 hours in the presence or absence of LBH589. DNA synthesis was measured as previously described.
13
Flow cytometric analysis
Cell-cycle analysis was profiled by flow cytometry using propidium iodide (PI) staining 
Statistical analysis
Statistical significance of differences in drug-treated versus control cultures was determined using Student's t-test. The minimal level of significance was P<0.05. Geneexpression profiling supervised clustering analysis has been performed using the dChip software (www.dchip.org) (P<0.05). miRNA expression data was analyzed according to manufacturer's instructions (Luminex, Houston, TX). The expression patterns of unfiltered data were performed using unsupervised hierarchical clustering of samples based on centroid linkage and 1-correlation distance metric, using dChip (www.dchip.org). To further define those miRNAs differentially expressed between groups (patients vs normal), the data were filtered on significance of differences using ANOVA test, (P < 0.01). To identify specific predicted miRNAs-targeted mRNAs, TargetScan, PicTar, and miRanda algorithms were used. 22, 23 To reduce the numbers of false positives, only putative target genes predicted by the three algorithms were considered.
RESULTS
Increased expression of miRNA-206 and decreased expression of miRNA-9* modulate histone acetylation in WM patients
We have previously demonstrated that bone marrow (BM)-derived WM CD19 + selected cells present with a specific miRNA signature which differentiates tumor cells from their normal cellular counterpart. 11 Among the deregulated miRNAs, miRNA-206 and -9* are respectively increased and decreased compared to normal cells (Fig.1 A; P<0.01). We next analyzed the predicted gene targets for miRNA-206 and -9*, using miRanda, TargetScan, and PicTar, algorithms commonly used to predict human miRNA gene targets 22, 23 and specifically identified genes predicted by all three methods. Predicted targets for the increased miRNA-206 and decreased miRNA-9* included histoneacetyltransferases (HATs) and histone-deacetylases (HDACs), respectively; leading us to hypothesize that miRNA-206 and -9* play a role in modulating the histone-acetylation status in primary WM cells. To determine whether an imbalance of HDAC/HAT activity occurs in WM, we first examined HDACs and HATs expression at the mRNA level in primary CD19+ cells isolated from WM patients compared to their cellular counterpart.
We found that primary WM cells were characterized by significant increased expression of HDAC-2, -4, -5, -6, -8, -9, and significant decreased expression of HAT-1, -2, and -3 (Fig. 1B) .
We next examined how this imbalance could affect acetylated-histone status and HDAC activity level. Therefore, acetylated histone-H3 and -H4, as well as HDAC activity have been evaluated in bone marrow derived CD19+ WM cells compared to their normal counterpart. HDAC activity in WM and other IgM-secreting low-grade lymphoma cell lines was also investigated. We found a lower level of acetylated histone H3 and H4 in primary CD19+ WM cells compared to control ( Fig. 2A-2B) . Conversely, the level of HDAC activity was significantly higher in all WM patient samples and cell lines compared to the average of 3 normal controls, indicating that indeed HDAC activity is elevated in WM cells (Fig. 2C ).
To further define the role of miRNA-206 and -9* in targeting histone-acetylation in WM cells as well as in other IgM-secreting low-grade lymphoma cell lines, acetylated-histones expression and HDAC activity were examined in miRNA-206 knockdown and miRNA-9*-precursor (pre-miRNA-9*)-transfected cells, compared to controls (controlprobe transfected-and untransfected cells). Efficiency of transfection was evaluated by
qRT-PCR at 48 hours after transfection (Suppl. Fig. 1A -B-C). We first investigated whether predicted HDAC4/HDAC5 and HAT (Myst3) mRNAs were targeted at the protein level by miRNA-9* and miRNA-206, respectively. We first demonstrated that miRNA-9* induces down-modulation of HDAC4 and HDAC5 without affecting Myst3 protein expression, as shown by western blot in precursor (pre)-miRNA-9*-transfected cells (Fig. 3A) , compared to either untransfected or scramble probe-transfected cells, used as controls. We also validated that miRNA-206 targets HAT (Myst3), as shown by up-regulation of Myst3 protein level in anti-miRNA-206-transfected cells compared to controls (Fig. 3B ). pre-miRNA-9*-and anti-mIRNA-206-dependent modulation of the relative targets was also confirmed at mRNA level (Suppl. Fig. 1D ). We also confirmed that acetyl histone-H3 and -H4 were upregulated in pre-miRNA-9*-and -anti-miRNA-206-transfected cells, with a higher acetyl histone-H3 and -H4 up-regulation upon miRNA-9* modulation (Fig. 3C) . We next investigated whether miRNA-9*-and -206-dependent regulation of acetyl histone-H3 and -H4 depends on changes in HDAC activity in cell lines; and found that HDAC activity was down-regulated in pre-miRNA-9*-transfected cells compared to either untransfected or scramble probe-transfected cells (Fig. 3D) . HDAC activity was not modified in anti-miRNA-206-transfected cells compared to controls (Fig. 3D ). Further validation of HDAC inhibition inducing upregulation of acetyl histone-H3 and -H4 in WM, as well in other IgM secreting low grade lymphoma cell lines, was demonstrated by Western blot in cells treated with the pan-HDAC inhibitor LBH589 in a dose-dependent manner (Fig. 3E) . Similarly, modulation of HDAC activity was observed in WM and other IgM secreting low grade lymphoma cell lines upon LBH-589 treatment in a dose-dependent manner (Fig. 3F) .
miRNA-9*-dependent regulation of proliferation and survival in WM cells
Based on the ability of miRNA-9* to modulate HDAC activity in WM cells, we next sought to determine the effect of miRNA-9* in regulating cell proliferation and survival.
We showed that DNA synthesis was significantly reduced in pre-miRNA-9*-transfected cells compared to control at both 48 hours and 72 hours (P <0.05; Fig. 4A ). In addition, induction of toxicity was observed in pre-miRNA-9*-transfected BCWM.1 cells compared to controls (P<0.05; Fig. 4A ). Similar results were confirmed in other IgM secreting low grade lymphoma cell lines, MEC.1 (Fig. 4B) and RL (Fig. 4C) . In contrast, DNA synthesis and toxicity were not demonstrated in anti-miRNA-206-transfected cells (Suppl. Fig. 2A-B-C) . To better define whether miRNA-9*-induced cytotoxicity is functionally related to HDAC inhibition, BCWM.1 cells were cultured in presence or absence of LBH589 50nM for 8 hours, washed, and subsequently transfected using premiRNA-9* probe, and harvested after 48 hours. Untransfected-untreated cells were used as control. We observed that pre-miRNA-9*-transfected cells did not present with significant increased toxicity as compared to LBH589-pretreated cells, suggesting that miRNA-9*-dependent induction of cell death is related to HDAC inhibition (Suppl. Fig   2D) . We next evaluated cell cycle profiling in pre-miRNA-9* transfected cells: increased number of cells in G1 phase was observed upon pre-miRNA-9* transfection (65% vs 53%), together with a decreased number of cells in S phase (20% vs 34%). It has been previously demonstrated that HDAC4 promotes the repression of cyclin-dependent kinase inhibitors p21. 24 We demonstrated that p21 expression was up-regulated in premiRNA-9*-transfected cells compared to either untransfected or scramble probetransfected cells (Fig. 4E ). Since p21 does not represent a miRNA-9*-predicted mRNA, this could possibly be driven by miRNA-9*-dependent HDAC4 modulation in WM cells.
To further validate the role of HDAC inhibition in reducing WM cell proliferation, the effect of the HDAC inhibitor LBH589 was next tested in primary WM cells. LBH589 Fig. 3B-3C ). We next confirmed that cell cycle progression was modulated upon HDAC inhibitor treatment. LBH589 induced subG1 arrest (1.5%, 5.9%, Fig. 3D ). To determine the mechanism of LBH589-induced cell cycle arrest, we investigated the effect of LBH589 on BCWM.1 cells using immunoblotting. BCWM.1 cells were treated with LBH589 (0-60 nM) for 16 hours. LBH589 induced the upregulation of cyclin kinase inhibitor proteins p21
Cip1 and p27 kip1 , as well as the downregulation of cyclin D2, and cyclin-dependent kinase (cdk2, cdk4) protein levels (Suppl. Fig. 3E ).
Mechanisms of miRNA-9*-dependent toxicity in WM cells
Cell cycle profiling was also able to show an up-regulation of sub-G1 phase in premiRNA-9*-transfected cells compared to controls (Fig. 4D) , indicating presence of apoptotic cells; indeed, induction of apoptosis was observed in pre-miRNA-9*-transfected cells, as shown by Apo2.7 staining and flow cytometry analysis (Fig. 5A ).
miRNA-9*-dependent modulation of apoptosis in WM cells was supported by PARP-, caspase-8-and caspse-9-cleavage as shown by Western blot in pre-miRNA-9*-transfected cells compared to either untransfected or scramble probe-transfected cells (Fig. 5B ).
To further confirm that miRNA-9*-dependent modulation of HDAC activity leads to toxicity in WM cells, the effect of LBH589 has been tested in WM cells. Histone acetylation regulates the function of many genes involved in cell survival. 10, 26 We therefore sought to examine the effect of LBH589 on the expression of proteins known to be regulated by histone acetylation; we observed an up-regulation of p53, together with down-regulation of BCL-XL, Mcl-1 and c-myc (Fig. 5C ). In addition, LBH589-dependent inhibition of HDACs resulted in the activation of both intrinsic and extrinsic apoptotic pathways with caspase-9, caspase-8, caspase-3, and PARP cleavage in a dosedependent manner (Fig. 5D) It has been demonstrated that HDAC inhibition leads to apoptosis though caspaseindependent mechanisms, such as inducing autophagy. 27, 28 We therefore evaluated the efficacy of miRNA-9* in modulating autophagy in WM cells; and found upregulation of Rab7 and LC3B in pre-miRNA-9*-transfected cells compared to either untransfected or scramble probe-transfected cells (Fig. 6A) . The effect of LBH589 in inducing autophagy was next evaluated. BCWM.1 cells were incubated with LBH589 (40 nM for 3, 6, 12, and 24 hours), and whole-cell extracts were then analyzed using immunoblotting. We found that LBH589 increased LC3B and Rab7 expression in a time-dependent manner (Fig. 6B) . We further confirmed that LC3B and Rab7 protein levels were upregulated by LBH589 in BCWM.1 cells using immunofluorescence ( Fig. 6C; Fig. 6D ). These data confirm that HDAC inhibition, due to either miRNA9*-dependent modulation or LBH589 treatment, results in induction of autophagy in WM cells.
Neither adherence to BMSCs nor growth factors protect against miRNA-9*-dependent effect on WM cells
Since the BM microenvironment confers growth and induces drug resistance in malignant cells, 29 we next investigated whether miRNA-9*-dependent modulation of WM cell proliferation and survival could inhibit WM cell growth even in the context of the BM milieu. Untransfected, scramble probe-transfected and pre-miRNA-9*-transfected WM cells were cultured in the presence or absence of BMSCs for 48 hours; we found that the adherence of untransfected, scramble probe, or pre-miRNA-9*-transfected BCWM.1 cells to BMSCs triggered an increase of 70%, 68%, and 47% in proliferation, respectively, as compared to untransfected, scramble probe-, and pre-miRNA-9* transfected cells cultured alone (Fig. 7A) , indicating the ability of miRNA-9* to inhibit WM cells proliferation, even in the presence of bone marrow milieu.
Previous studies using gene expression analysis in WM have demonstrated an upregulation in IL-6 signaling. 30 IL-6 also promotes plasmacytoid lymphocyte growth in WM, and serum IL-6 levels reflect tumor burden and disease severity. 31 Similarly, it has been previously shown that IGF-1 induces the proliferation of WM cells. 16 We therefore next tested whether the addition of recombinant human IL-6 (25 ng/mL) or IGF-1 (50 ng/mL) can overcome miRNA-9*-dependent WM cytotoxicity. Both IL-6 and IGF-1 induced proliferation of either untransfected or scramble probe-transfected cells, in contrast with pre-miRNA-9*-transfected cells where IL-6 and IGF-1 did not exert any pro-proliferative effect (Fig. 7B) .
To Fig. 7D ).
For
DISCUSSION
Alterations in the balance between HAT and HDAC activity in many cancers will lead to deregulated gene expression and the induction of proliferation and survival in tumor cells. [5] [6] [7] [8] [9] [10] HDACs mediate the function of oncogeneic translocations in many malignancies including PML-RAR in acute promyelocytic leukemia. 32 Most of the aberrant HAT and HDAC activity has been due to translocation, amplification, overexpression or mutation in many malignancies, including hematological malignancies. probe-and pre-miRNA-9*-transfected) were harvested at 12 hours after transfection.
Whole cell lysates were subjected to Western blotting using anti-p21 and -actin antibodies. (F) Freshly isolated normal CD19+ cells from normal PBMCs were cultured with LBH589 (0-80 nM) for 48 hours. Cytotoxicity was assessed by MTS assay. 
